HLS Therapeutics Inc.
HLS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.21% | -46.74% | 37.59% | 14.75% | 6.94% |
| Total Depreciation and Amortization | 2.29% | -1.36% | -1.34% | -5.94% | -1.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.73% | -16.15% | -4.31% | -44.41% | 126.20% |
| Change in Net Operating Assets | -34.12% | 39,080.00% | -350.00% | -99.76% | 180.07% |
| Cash from Operations | 29.95% | 10.55% | 113.52% | -40.41% | 223.78% |
| Capital Expenditure | -314.29% | -61.54% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Investing | -5,076.19% | -61.54% | 99.13% | -111.32% | 662,600.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -178.18% | -16.92% | 82.42% | -840.56% | 27.64% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -373.30% | -- | -- | 100.00% | -12.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -23.45% |
| Cash from Financing | -188.66% | -23.55% | 82.42% | -485.12% | 14.96% |
| Foreign Exchange rate Adjustments | 948.57% | 105.63% | -618.33% | 202.56% | 53.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,107.55% | 430.95% | 99.44% | -214.56% | 621.00% |